JERUSALEM--(BUSINESS WIRE)--Jun. 5, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) will host a live audio webcast at the Goldman Sachs 35th Annual Global Healthcare Conference. Eyal Desheh, EVP & CFO will present on Tuesday, June 10, 2014 at 2 PM PT. What:   Teva Presentation at the Goldman Sachs 35th Annual Global Healthcare Conference   Who: ...

Adds LBR-101, Labrys’ Phase IIb anti-CGRP monoclonal antibody for the prevention of chronic and high frequency episodic migraine. Peak sales potential of $2-3 billion. Teva ideally positioned in the transformational pain market with a wide range of new chemical and biologic entities and NTEs to treat a broad spectrum of pain disorders JERUSALEM & SAN MATEO, Calif.--(BUSINESS WIRE)--Jun. 3, 2014-- Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) and Labrys Biologics, Inc., a privately-held development stage biotechnology company focused on treatments for chronic migraine and episodic migraine,...

APPOINTS SIGURDUR OLAFSSON AS PRESIDENT AND CEO OF NEWLY ESTABLISHED GLOBAL GENERIC MEDICINES GROUP New, fully integrated Global Generic Medicines Group will be responsible for all global commercial activity Newly formed Corporate Development, Strategy and Innovation Group, with broader scope Establishes Global Corporate Marketing Excellence and Communications Group Appoints new Global Head of Quality Lean, focused, integrative structure will reduce Teva's executive committee from 15 to 9 members (reporting to the CEO) ...

JERUSALEM--(BUSINESS WIRE)--May 30, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced that the U.S. District Court for the Northern District of West Virginia denied a motion filed by Mylan and issued an opinion and order affirming a decision by the FDA under which Teva should receive sole 180-day “first-to-file” exclusivity for generic Celebrex® (celecoxib) 100, 200 and 400 mg capsules. On April 17th,Teva entered into a settlement agreement with Pfizer related to Teva’s generic version of Celebrex® (celecoxib) 50, 100, 200 and 400 mg capsules in the United States. Under the terms of the settlement, T...

JERUSALEM--(BUSINESS WIRE)--May 29, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) will host a live audio webcast at the Jefferies 2014 Global Healthcare Conference. Jon Congleton, SVP & Head of Global CNS will present on Tuesday, June 3, 2014 at 9:00 AM ET. What: Teva Presentation at the Jefferies 2014 Global Healthcare Conference Who: Jon Congleton, SVP & Head of Global CNS, Teva Pharmaceutical Industries Ltd. When: Tuesday, June 3, 2014 Where: www.tevapharm.com How: Live over the Internet – log on to the Web at the address above and register for the e...

JERUSALEM--(BUSINESS WIRE)--May 27, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced that the European Patent Office issued a decision in favor of Teva in a patent opposition proceeding filed by Synthon BV, Mylan and an unidentified third party. On September 6, 2012, the three opponents commenced an opposition proceeding against European Patent EP 2 177 528, a patent for COPAXONE® (glatiramer acetate injection) expiring September 9, 2025. In today's hearing, the European Patent Office specifically determined that claims 1-12 of the '528 patent are valid. Therefore infringing follow-on glatiramer products would not...

All Teva Respiratory Brands in the United States Will Soon Be Available With a Dose Counter JERUSALEM--(BUSINESS WIRE)--May 23, 2014-- Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved the use of QVAR® (beclomethasone dipropionate HFA) with a dose counter for the ongoing treatment of asthma as a preventative therapy in patients five years of age and older. The dose counter is designed to help asthma patients, as well as their caregivers, keep track of the number of doses remaining in the canister. The new product will be commercially available later ...

JERUSALEM & LUND, Sweden--(BUSINESS WIRE)--May 23, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Active Biotech (NASDAQ OMX NORDIC:ACTI) announced today that the Committee for Medicinal Products for Human Use (CHMP) confirmed its January 23, 2014 opinion to recommend against approval for the treatment of relapsing-remitting multiple sclerosis (RRMS) in the European Union (EU) at this time. Both companies remain committed to the NERVENTRA® (laquinimod) clinical development program for multiple sclerosis (MS) and are focused on evaluating the CHMP feedback to determine potential next steps. ...

JERUSALEM--(BUSINESS WIRE)--May 15, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) will host a live audio webcast at the UBS Global Healthcare Conference. Eyal Desheh, EVP & CFO will present on Monday, May 19, 2014 at 1:00 PM ET. What: Teva Presentation at the UBS Global Healthcare Conference Who: Eyal Desheh, EVP and CFO, Teva Pharmaceutical Industries Ltd. When: Monday, May 19, 2014 Where: www.tevapharm.com How: Live over the Internet – log on to the Web at the address above and register for the event (approximately 10 minutes before). An archive of the webca...

First waterless corticosteroid nasal spray to apply for pediatric approval JERUSALEM--(BUSINESS WIRE)--May 13, 2014-- Teva Pharmaceuticals Industries Ltd., (NYSE:TEVA) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s supplemental new drug application (sNDA) for a lower dose QNASL® (beclomethasone dipropionate) Nasal Aerosol for the treatment of seasonal and perennial allergic rhinitis in children 4-11 years of age. QNASL is a waterless intranasal corticosteroid spray currently available for the treatment of nasal symptoms of seasonal allergic rhinitis (SAR) and pere...